Comparative Pharmacology
Head-to-head clinical analysis: ORALTAG versus PEPCID AC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORALTAG versus PEPCID AC.
ORALTAG vs PEPCID AC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naloxegol is a PEGylated naloxol derivative that acts as a peripherally acting mu-opioid receptor antagonist. It blocks opioid binding at mu-receptors in the gastrointestinal tract, reversing opioid-induced constipation without compromising central analgesia due to limited blood-brain barrier penetration.
Competitive antagonist of histamine H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion.
IV: 4 mg/kg every 12 hours; Oral: 10 mg/kg every 12 hours, max 400 mg/dose.
20 mg orally twice daily for 12 weeks for erosive esophagitis; 20 mg orally once daily for 4-8 weeks for GERD; 10 mg orally once daily for OTC use for heartburn.
None Documented
None Documented
Terminal elimination half-life is approximately 8-12 hours in adults with normal renal function; prolonged to 15-30 hours in renal impairment (CrCl <30 mL/min).
2.5-3.5 hours (prolonged in renal impairment, e.g., CrCl <30 mL/min: up to 20 hours)
Primarily renal excretion of unchanged drug (approx. 70%) and its glucuronide conjugate (approx. 20%); biliary/fecal elimination accounts for <10%.
Renal (65-70% as unchanged drug), hepatic metabolism (minor), biliary/fecal (approx. 30%)
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist